ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

ViroPharma Inc. (VPHM)

Q2 2012 Earnings Call

August 9, 2012 9:00 am ET

Executives

Vincent J. Milano – Chairman, President and Chief Executive Officer

J. Peter Wolf – Vice President, General Counsel and Secretary

Charles A Rowland – Vice President, Chief Financial Officer

Colin Broom – Vice President and Chief Scientific Officer

Daniel B. Soland – Vice President and Chief Operating Officer

Analysts

Brian Abrahams – Wells Fargo Securities

Geoff Meacham – JPMorgan

Thomas Wei – Jefferies & Company

Rachel McMinn – Bank of America Merrill Lynch

Lisa Bayko – JMP Securities

Brian Skorney – Brean Murray

Mario Corso – Caris & Company

Philip Nadeau – Cowen & Company

Stephen Willey – Stifel Nicolaus & Company, Inc.

Joseph Schwartz – Leerink Swann Llc

Presentation

Operator

Good morning everyone, and welcome to the ViroPharma Second Quarter 2012 Results Conference Call. Today’s call is being recorded and is expected to last one hour. At this time, I will now turn the call over to ViroPharma’s Chief Executive Officer, Vin Milano. Please go ahead.

Vincent J. Milano

Thank you, Operator. Good morning, and welcome to everyone joining us on today’s call to discuss our performance for the second quarter of 2012. I’m joined by the other members of the ViroPharma management team, as well as Rich Morris, Will Roberts, and Bob Doody. Before we proceed, Pete Wolf, our General Counsel will provide you of our potential to make forward-looking statements. Pete?

J. Peter Wolf

Thanks, Vin. During this call, we will make forward-looking statements certain statements such as those regarding our expectations for financial results including guidance, peak year, net sales for Cinryze, peak year European net sales and tax rates, manufacturing capacities, the timing of clinical studies, potential or product candidates and clinical development, changes in channel inventory, our commercial launches of Cinryze, Plenadren and Buccolam in Europe and our ability to continue to identify additional Cinryze patients are examples of such forward looking statements.

If you liked this article you might like

Acting FTC Chairman Says Deal with China with Carrots and Sticks

Shire Quickly Pulls Off Dermagraft

Market Up on Deals, Results

Shire Deal Just The Start

Upbeat China Data Kickstarts Week